Neuroimaging for optimization of stem cell therapy in Parkinson's disease

Bibliography

• Brundin P, Barker RA, Parmar M. Neural grafting in Parkinson's disease Problems and possibilities. Prog Brain Res 2010;184:265-94
   PubMed Web of Science ®Google Scholar
• Liu S-P, Fu R-H, Huang S-J, et al. Stem cell applications in regenerative medicine for neurological disorders. Cell Transplant 2013;22:631-7
   PubMed Web of Science ®Google Scholar
• Hayashi T, Shimazawa M, Watabe H, et al. Kinetics of neurodegeneration based on a risk-related biomarker in animal model of glaucoma. Mol Neurodegener 2013;8:4
   PubMedGoogle Scholar
• Thompson L, Barraud P, Andersson E, et al. Identification of dopaminergic neurons of nigral and ventral tegmental area subtypes in grafts of fetal ventral mesencephalon based on cell morphology, protein expression, and efferent projections. J Neurosci Off J Soc Neurosci 2005;25:6467-77
   PubMed Web of Science ®Google Scholar
• Grealish S, Jönsson ME, Li M, et al. The A9 dopamine neuron component in grafts of ventral mesencephalon is an important determinant for recovery of motor function in a rat model of Parkinson's disease. Brain 2010;133:482-95
   PubMed Web of Science ®Google Scholar
• Kriks S, Shim J-W, Piao J, et al. Dopamine neurons derived from human ES cells efficiently engraft in animal models of Parkinson's disease. Nature 2011;480:547-51
   PubMed Web of Science ®Google Scholar
• Doi D, Morizane A, Kikuchi T, et al. Prolonged maturation culture favors a reduction in the tumorigenicity and the dopaminergic function of human ESC-derived neural cells in a primate model of Parkinson's disease. Stem Cells 2012;30:935-45
   PubMed Web of Science ®Google Scholar
• Hayashi T, Wakao S, Kitada M, et al. Autologous mesenchymal stem cell-derived dopaminergic neurons function in parkinsonian macaques. J Clin Invest 2013;123:272-84
   PubMed Web of Science ®Google Scholar
• Fu Y, Yuan Y, Halliday G, et al. A cytoarchitectonic and chemoarchitectonic analysis of the dopamine cell groups in the substantia nigra, ventral tegmental area, and retrorubral field in the mouse. Brain Struct Funct 2012;217:591-612
   PubMed Web of Science ®Google Scholar
• Burbach JPH, Smidt MP. Molecular programming of stem cells into mesodiencephalic dopaminergic neurons. Trends Neurosci 2006;29:601-3
   PubMed Web of Science ®Google Scholar
• Takagi Y, Takahashi J, Saiki H, et al. Dopaminergic neurons generated from monkey embryonic stem cells function in a Parkinson primate model. J Clin Invest 2005;115:102-9
   PubMed Web of Science ®Google Scholar
• Muramatsu S-I, Okuno T, Suzuki Y, et al. Multitracer assessment of dopamine function after transplantation of embryonic stem cell-derived neural stem cells in a primate model of Parkinson's disease. Synapse 2009;63:541-8
   PubMed Web of Science ®Google Scholar
• Kikuchi T, Morizane A, Doi D, et al. Survival of Human Induced Pluripotent Stem Cell–Derived Midbrain Dopaminergic Neurons in the Brain of a Primate Model of Parkinson's Disease. J Park Dis 2011;1(4):395-412
   Google Scholar
• Dhawan V, Ishikawa T, Patlak C, et al. Combined FDOPA and 3OMFD PET studies in Parkinson's disease. J Nucl Med Off Publ Soc Nucl Med 1996;37:209-16
   Google Scholar
• Politis M, Wu K, Loane C, et al. Serotonergic neurons mediate dyskinesia side effects in Parkinson's patients with neural transplants. Sci Transl Med 2010;2:38ra46
   PubMed Web of Science ®Google Scholar
• Shukuri M, Takashima-Hirano M, Tokuda K, et al. In vivo expression of cyclooxygenase-1 in activated microglia and macrophages during neuroinflammation visualized by PET with 11C-ketoprofen methyl ester. J Nucl Med 2011;52:1094-101
   PubMed Web of Science ®Google Scholar
• Mendez I, Sanchez-Pernaute R, Cooper O, et al. Cell type analysis of functional fetal dopamine cell suspension transplants in the striatum and substantia nigra of patients with Parkinson's disease. Brain J Neurol 2005;128:1498-510
   Google Scholar
• Piccini P, Brooks DJ, Björklund A, et al. Dopamine release from nigral transplants visualized in vivo in a Parkinson's patient. Nat Neurosci 1999;2:1137-40
   PubMed Web of Science ®Google Scholar
• Wu T, Long X, Zang Y, et al. Regional homogeneity changes in patients with Parkinson's disease. Hum Brain Mapp 2009;30:1502-10
   PubMed Web of Science ®Google Scholar
• Picconi B, Centonze D, Rossi S, et al. Therapeutic doses of L-dopa reverse hypersensitivity of corticostriatal D2-dopamine receptors and glutamatergic overactivity in experimental parkinsonism. Brain J Neurol 2004;127:1661-9
   Google Scholar
• Poston KL, Eidelberg D. Network biomarkers for the diagnosis and treatment of movement disorders. Neurobiol Dis 2009;35:141-7
   PubMed Web of Science ®Google Scholar
• Baudrexel S, Witte T, Seifried C, et al. Resting state fMRI reveals increased subthalamic nucleus-motor cortex connectivity in Parkinson's disease. Neuroimage 2011;55(4):1728-38
   PubMed Web of Science ®Google Scholar
• de la Fuente-Fernández R, Ruth TJ, Sossi V, et al. Expectation and dopamine release: mechanism of the Placebo Effect in Parkinson's disease. Science 2001;293:1164-6
   PubMed Web of Science ®Google Scholar
• Lindvall O, Kokaia Z, Martinez-Serrano A. Stem cell therapy for human neurodegenerative disorders-how to make it work. Nat Med 2004;10(Suppl):S42-50
   PubMed Web of Science ®Google Scholar
• Lindvall O, Björklund A. Cell therapeutics in Parkinson's disease. Neurother J Am Soc Exp Neurother 2011;8:539-48
   Google Scholar